0001567619-18-003079.txt : 20180924
0001567619-18-003079.hdr.sgml : 20180924
20180924205915
ACCESSION NUMBER: 0001567619-18-003079
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180920
FILED AS OF DATE: 20180924
DATE AS OF CHANGE: 20180924
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ensey Christopher
CENTRAL INDEX KEY: 0001730045
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33675
FILM NUMBER: 181084558
MAIL ADDRESS:
STREET 1: 1200 STEWART ST. UNIT 527
CITY: BALTIMORE
STATE: MD
ZIP: 21230
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Riot Blockchain, Inc.
CENTRAL INDEX KEY: 0001167419
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 841553387
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 202 6TH STREET, SUITE 401
CITY: CASTLE ROCK
STATE: CO
ZIP: 80104
BUSINESS PHONE: 303-794-2000
MAIL ADDRESS:
STREET 1: 202 6TH STREET, SUITE 401
CITY: CASTLE ROCK
STATE: CO
ZIP: 80104
FORMER COMPANY:
FORMER CONFORMED NAME: Bioptix, Inc.
DATE OF NAME CHANGE: 20161201
FORMER COMPANY:
FORMER CONFORMED NAME: Venaxis, Inc.
DATE OF NAME CHANGE: 20121218
FORMER COMPANY:
FORMER CONFORMED NAME: AspenBio Pharma, Inc.
DATE OF NAME CHANGE: 20051110
4
1
doc1.xml
FORM 4
X0306
4
2018-09-20
0
0001167419
Riot Blockchain, Inc.
RIOT
0001730045
Ensey Christopher
C/O RIOT BLOCKCHAIN, INC.
202 6TH STREET, SUITE 401
CASTLE ROCK
CO
80104
0
1
0
0
Interim CEO
Common Stock
2018-09-20
4
M
0
24000
0.00
A
74000
D
Restricted Stock Unit
2018-09-20
4
M
0
24000
0.00
A
Common Stock
24000
24000
D
Represents the 24,000 vested Restricted Stock Units ("RSUs") reported in Column 5 of Table I on page one above, convertible into shares of the Issuer's Common Stock on a one-for-one basis pursuant to the Riot Blockchain, Inc. (f/k/a Bioptix, Inc.) Amended & Restated Equity Incentive Plan (the "Plan").
Represents a restricted stock award granted to the Reporting Person by the Issuer under the Plan at no cost on September 20, 2018 in connection with the Reporting Person's appointment as interim Chief Executive Officer, which award vested on the date of grant, subject to the restrictions of the Plan.
Includes a restricted stock option award of the option to purchase 50,000 shares of Common Stock granted on January 27, 2018 in connection with the Reporting Person's appointment as Chief Operating Officer, which option shall vest in 24 equal monthly installments over a two year period, beginning on the one month anniversary of the date of issuance at an option price of $18.50 per share.
Not applicable.
Represents only the 24,000 RSUs granted on September 20, 2018 and does not include RSUs previously reported.
/s/ Christopher Ensey
2018-09-24